Inhibitors in the Swedish population with severe haemophilia A and B: A 20-year survey

Acta Paediatrica, International Journal of Paediatrics

Volumn 91, Issue 8, 2002, Pages 910-914

  Knobe, K E ^a   Sjorin E ^a   Tengborn, L I ^a   Petrini, P ^b   Ljung, R C R ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska Hospital ^*  (Sweden)

Author keywords

Factor IX; Factor VIII; Haemophilia A; Haemophilia B; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ARTICLE; BLOOD; CHILD; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEALTH SURVEY; HEMOPHILIA A; HEMOPHILIA B; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; PRESCHOOL CHILD; SWEDEN; TIME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEALTH SURVEYS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INCIDENCE; INFANT; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS;

EID: 0036044248     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/080352502760148621     Document Type: Article

References (28)

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
2. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
4. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
5. Prevalence of inhibitors in a population of 3435 hemophilia patients in France
6. Prevalence of Factor IX inhibitors among patients with haemophilia B: Results of a large scale North American survey
7. Retrospective study of inhibitor formation in Japanese hemophiliacs
8. Haemophilia B mutations in Sweden: A population based study of mutational heterogeneity
9. Antibodies to blood coagulation factors
10. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder
11. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII
12. Gene deletions in patients with haemophilia B and anti-factor IX antibodies
13. Haemophilia A: Mutation type determines risk of inhibitor formation
14. Gene mutations and inhibitor formation in patients with hemophilia B
15. Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase
16. Haemophilia B mutations in a complete Swedish population sample: A test of new strategy for the genetic counselling of diseases with high mutational heterogeneity
17. Proceedings: A more uniform measurement of factor VIII inhibitors
18. Factor VIII and factor IX inhibitors in haemophiliacs
19. Treatment of children with haemophilia in Europe: A survey of 20 centres in 16 countries
20. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (recombinate)
21. Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B
22. Mutations in severe hemophilia A: Distribution within the factor VIII gene, origin and influence on inhibitor development
23. Factor IX inhibitors and anaphylaxis in hemophilia B
24. The Malmö model for immune tolerance induction: Role of previous treatment on the success of immune tolerance
25. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
26. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate